AstraZeneca Downsizing R&D Staff

Positions for 1,600 scientists at the pharmaceutical company will be eliminated globally.

By | March 19, 2013

WIKIMEDIA, LUKE-2The pharmaceutical company AstraZeneca will eliminate 1,600 R&D positions worldwide and will move many jobs to new facilities. The decision, announced yesterday (March 18), comes at a time when the company is facing declining profits and competition from generic drugs, the Associated Press reported.

“This is a major investment in the future of this company that will enable us to accelerate innovation by improving collaboration, reducing complexity, and speeding up decision-making,” said Pascal Soriot, the company’s CEO, in a statement.

At the company’s center in Wilmington, Delaware, 650 positions will be eliminated, while another 550 will move elsewhere, including to the company’s facility in Gaithersburg, Maryland.

The facility at Alderley Park in northwestern England will no longer have R&D employees. Many of these positions will be transferred to a $500 million center the company is building in Cambridge, England.

Earlier this year, the company cut 2,200 R&D jobs. Soriot, who became CEO in October, is expected to announce his strategic plan to investors later this month. The current restructuring will cost $1.4 billion now but should save the company $190 million annually when all the cuts go into effect, AstraZeneca’s statement said.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham